Positive Results Seen With Voxelotor in Pediatric Patients With Sickle Cell Disease
Researchers sought to determine whether the use of voxelotor in a younger population of patients with sickle cell disease would be safe and effective.
Diagnosis & Disease Information
Belumosudil Yields Clinically Meaningful Outcomes in Patients With Chronic Graft-Vs-Host Disease
Researchers sough to determine whether belumosudil would help treat patients with chronic GVHD.
Mitapivat Induces Responses in Patients With Thalassemia
Researchers sought to determine whether mitapivat would improve clinical outcomes in patients with thalassemias who are not transfusion-dependent.
First-in-Human Results Show Promise With BT200, a New Anti-von Willebrand Factor Agent
Researchers sought to determine whether BT200, a new anti-von Willebrand factor, would have efficacy in patients with von Willebrand disease.
Iptacopan Shows Promise in First Line Treatment of Paroxysmal Nocturnal Hemoglobinuria
Researchers sought to determine whether iptacopan would have efficacy in first line treatment of patients with PNH.
Lower Mutation Burden With Pevonedistat Plus Azacitidine Vs Azacitidine Alone in Patients With Myelodysplastic Syndromes
Researchers sought to determine whether pevonedistat plus azacitidine would result in a lower residual mutation load than seen with azacitidine alone in patients with MDS.
Iberdomide-Based Regimens Show Promise in Relapsed/Refractory Multiple Myeloma
The median duration of response was 35.7 weeks with iberdomide, bortezomib, and dexamethasone compared with not reached in patients who received iberdomide, daratumumab, and dexamethasone or iberdomide, bortezomib, and carfilzomib
Long-Term Follow-Up Data Support Adding Daratumumab to Lenalidomide/Dexamethasone in Transplant-Ineligible MM
The median progression-free survival was not reached in the D-Rd group compared with 34.4 months in the Rd group.
Continued Benefit Observed With Isatuximab Plus Pomalidomide and Dexamethasone in Multiple Myeloma
Adding isatuximab to pomalidomide and dexamethasone improved progression-free survival (PFS) and PFS2.
Relapsed, Refractory Follicular Lymphoma: CAR-T Cell Therapy Shows Promise
In patients who had received at least 2 prior therapy lines, the overall response rates were 49.9% in SCHOLAR-5 vs 94.2% in ZUMA-5.
- Loading...
Loading...
Next post in Lymphoma
Loading... 
Loading...